Lucy Therapeutics develops treatments for mitochondrial diseases and neurodegenerative disorders by targeting mitochondrial proteins.
Lucy Therapeutics has raised $12.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2024.
Lucy Therapeutics's investors include Engine Ventures, Safar Partners, The Engine, Michael J. Fox Foundation, Massachusetts Life Sciences Center.
Lucy Therapeutics is headquartered in Cambridge, United States.
Lucy Therapeutics develops treatments for mitochondrial diseases and neurodegenerative disorders by targeting mitochondrial proteins.
Lucy Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lucy Therapeutics — Funding & Investors." VCBacked, May 28, 2024, https://www.vcbacked.co/company/lucy-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Lucy Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/lucy-therapeutics
{{cite web |title=Lucy Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lucy-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated